Searching across hundreds of databases

Our searching services are busy right now. Your search will reload in five seconds.

  • Register
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.


Leaving Community

Are you sure you want to leave this community? Leaving the community will revoke any permissions you have been granted in this community.

Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

Preparing word cloud



Type in a keyword to search

Filter by last modified time
See new records

Current Facets and Filters

  • Keywords:clinical (facet)


Sort alphabetically | Sort by count

Recent searches

SciCrunch Registry is a curated repository of scientific resources, with a focus on biomedical resources, including tools, databases, and core facilities - visit SciCrunch to register your resource.

(last updated: Aug 10, 2019)

Physical Resource or Software Tool Software

513 Results - per page

Resource NameResource TypeDescriptionKeywordsResource IDProper CitationParent OrganizationRelated ConditionFunding AgencyRelationReferenceWebsite StatusAlternate IDsAlternate URLsOld URLs
SyapseResource, software resource, service resource, commercial organizationA platform and application suite for bringing together omics and clinical data.medicine, molecular profiling, omics, clinicalSCR_012023(Syapse, RRID:SCR_012023)listed by: OMICtoolsLast checked upOMICS_02092
National Center for Image-Guided TherapyResource, biomedical technology research center, training resourceBiomedical Technology Resource Center that serves as a national resource for all aspects of research into medical procedures that are enhanced by imaging. Its common goal is to provide more effective patient care. The center is focused on the multidisciplinary development of innovative image-guided intervention technologies to enable effective, less invasive clinical treatments that are not only more economical, but also produce better results for patients. The NCIGT is helping to implement this vision by serving as a proving ground for some of the next generation of medical therapies.clinical, patient care, imaging, medical procedureSCR_001419(National Center for Image-Guided Therapy, RRID:SCR_001419)Harvard Medical School; Massachusetts; USA NIBIBLast checked upnlx_152641
Spinal ResearchResource, graduate program resourceSpinal Research is committed to funding the highest quality international research into a cure for spinal cord paralysis. They support both basic science and clinical research and aim to increase research capacity by encouraging talented young graduates into the field through their PhD studentships. Spinal Research funds studies in the most promising areas of research. With their funding, scientists have shown that each of tested approaches can regenerate damaged neurons in the spinal cord and has the potential to restore meaningful function to an injured patient. It is important that research continues in each area, because, as yet, no one knows which is likely to be the most successful. In fact, a combination of approaches is likely to be most effective. Research may be centered at the bench but to be productive requires collaboration and a healthy exchange of ideas. ISRT facilitates this by bringing our scientists together every year at their Annual Network Meetings, the first in this field, and publish an Annual Research Review a compilation of reports from their grant holders documenting their most recent developments. ISRT continually encourages international cooperation of effort and as a founding member of the ICCP (International Campaign for Cures of spinal cord injury Paralysis), ISRT has been instrumental in bringing essential guidelines on the conduct of safe and effective clinical trials for spinal cord injury. The Trust boasts an internationally-recognized Scientific Committee who guide their scientific strategy and preside over a peer-review process that ensures awards are made only to the highest quality research projects. Spinal Research recognizes that for complex multisystem diseases and pathologies, such as spinal cord injury, it is sometimes necessary to use animals as part of the overall research endeavor. However, Spinal Research is aware of the responsibility that this places on it to ensure, whenever possible, alternatives to the use of animals are explored. All laboratories must hold a certificate issued by the Home Office and have gained approval for their work from a local ethical and animal welfare committee before any work involving the use of animals is permitted.function, funding, animal, clinical, clinical trial, cure, damage, disease, graduate, injury, multisystem, neuron, paralysis, pathology, patient, research, science, scientist, spinal, spinal cord, studentship, testingSCR_002736(Spinal Research, RRID:SCR_002736)Last checked upnif-0000-24038
CelgeneResource, organization portal, commercial organization, production service resource, chemical supplier, material service resource, service resource, portal, reagent supplier, material resource, reagent manufacture, data or information resourceAn American global biotechnology company that manufactures drug therapies for cancer and inflammatory disorders. The company's major products are Thalomid (thalidomide), which is approved for the acute treatment of the cutaneous manifestations of moderate to severe erythema nodosum leprosum (ENL), as well as in combination with dexamethasone for patients with newly diagnosed multiple myeloma, and Revlimid (lenalidomide), for which the company has received FDA and EMA approval in combination with dexamethasone for the treatment of multiple myeloma patients who have received at least one prior therapy. Revlimid is also approved in the United States for the treatment of patients with transfusion-dependent anemia due to Low- or Intermediate-1-risk Myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities. Both Thalomid and Revlimid are sold through proprietary risk-management distribution programs to ensure safe and appropriate use of these pharmaceuticals. Vidaza is approved for the treatment of patients with MDS. Celgene also receives royalties from Novartis Pharma AG on sales of the entire Ritalin family of drugs, which are widely used to treat Attention Deficit Hyperactivity Disorder (ADHD). (Adapted from Wikipedia) There are numerous clinical trials at major medical centers using compounds from Celgene. Investigational compounds are being studied for patients with incurable hematological and solid tumor cancers, including multiple myeloma, myelodysplastic syndromes, chronic lymphocyte leukemia (CLL), non-Hodgkin's lymphoma (NHL), glioblastoma, and ovarian, pancreatic and prostate cancer.biopharmaceutical, drug, immune, inflammatory, clinical, medical, hematological, tumor, myeloma, myelodysplatic, syndrome, lymphocyte, leukemia, lymphoma, glioblastoma, ovarian, pancreatic, prostate, medicine, biotechnologySCR_002955(Celgene, RRID:SCR_002955)Cancer, Immune disease, Inflammatory disease, Attention-Deficit Hyperactivity Disorderuses: FluoroFinderLast checked upnif-0000-30309
Vascular Access Society of the AmericasResource, portal, community building portal, data or information resourceSociety devoted to the advancement of the field of dialysis access through research, education and advocacy for patients with end stage kidney disease. They provide vascular access education for physicians, nurses, and other health care professionals and advocate for evidenced-based best clinical practices.dialysis, kidney, clinical, vascularSCR_004058(Vascular Access Society of the Americas, RRID:SCR_004058)End stage kidney diseaserelated to: Kidney Health InitiativeLast checked upnlx_158492
T1D Exchange BiobankResource, service resource, data or information resource, material storage repository, storage service resource, biobankCollection of biological samples linked to participant medical data from individuals living with type 1 diabetes. Unifies samples and data from eight different clinical studies related to type 1 diabetes.collection, biological, sample, data, clinical, diabetesSCR_017195(T1D Exchange Biobank, RRID:SCR_017195)T1D Exchange type 1 diabetesLast checked up
Ludwig Boltzmann Cluster Translationale OnkologieResource, topical portal, portal, data or information resourceThe projected cluster includes the LBIs for Applied Cancer Research, Clinical Oncology and Photodynamic Therapy, Gynecology and Gynecologic Oncology, Stem Cell Transplantation and Surgical Oncology. The aim of the projected cluster Translational Oncology is the cooperative investigation of genetic and molecular biological characteristics of the tumor cells involved in minimal residual disease (MRD) in vitro and translation of the experimental and diagnostic results into the clinical practice involving therapeutic modalities with the newest generation of antitumoral drugs. Minimal residual disease is the designation for the occurrence of a low number of tumor cells remaining clinically undetected following curative therapy that give rise to tumor relapses. MRD is a central question in cancer therapy, since a major subpopulation of patients which underwent curative resection and therapy ultimately relapse and would have received more aggressive adjuvant therapy, provided that residual disease had been clearly proven. Otherwise low-risk patients would have not been treated aggressively in an adjuvant setting. MRD can be detected by methods in bone marrow or by extremely sensitive PCR (polymerase-chain-reaction)-based methods in peripheral blood. PCR-based methods allow for the characterization of tumor-specific gene expression in circulating tumor cells and thereby provide additional information in regard to malignity of cells and prognosis. The different participating institutions have extensive experience in patient care, organization of clinical studies and laboratory investigation. In particular, expert knowledge in stem cell transplantation and histological detection of MRD, multicentric clinical testing of new anticancer drugs, specialized treatment of various selected tumor entities such as neuroendocrine tumors, gene expression analysis of circulating tumor cells and tumor signatures, and in vitro characterization of chemosensitivity as well as tumor cell biology have been acquired at the individual LBIs in the past and are complementary to each other to be combined in a larger cluster structure. The detection of circulating tumor cells will be supported by ongoing EU (OVCAD OVarian CAncer Diagnosis) and GenAU projects aiming at identification of ovarian cancer cells in the blood. The assessment of methylated DNA sequences (suppressor genes) in peripheral blood as an indicator of MRD can be performed with the help of OncoLab Diagnostics GmbH. Cooperative action in this cluster, using a common tumor bank/clinical data collection and the combined clinical and experimental efforts are the base for the execution of the presented MRD project.cancer, tumor, clinical, oncology, photodynamic therapy, gynecology, gynecologic oncology, stem cell transplantation, surgical oncology, tumor cellSCR_000020(Ludwig Boltzmann Cluster Translationale Onkologie, RRID:SCR_000020)Last checked upnlx_143958
BioSpaceResource, narrative resource, data or information resource, job resourceOnline community for industry news and careers for life science professionals.biotechnology, pharmaceutical, career, clinical, academic, biomedical, medical deviceSCR_012010(BioSpace, RRID:SCR_012010)listed by: OMICtoolsLast checked upOMICS_01828
Family Investigation of Nephropathy of Diabetes Resource, resource, clinical trialMulticenter observational study designed to identify genetic determinants of diabetic nephropathy. It is conducted in eleven U.S. clinical centers and a coordinating center, and with four ethnic groups (European Americans, African Americans, Mexican Americans, and American Indians). Two strategies are used to localize susceptibility genes: a family-based linkage study and a case-control study using mapping by admixture linkage disequilibrium (MALD). In the family-based study, probands with diabetic nephropathy are recruited with their parents and selected siblings. Linkage analyses will be conducted to identify chromosomal regions containing genes that influence the development of diabetic nephropathy or related quantitative traits such as serum creatinine concentration, urinary albumin excretion, and plasma glucose concentrations. Regions showing evidence of linkage will be examined further with both genetic linkage and association studies to identify genes that influence diabetic nephropathy or related traits. Two types of MALD studies are being done. One is a case-control study of unrelated individuals of Mexican American heritage in which both cases and controls have diabetes, but only the case has nephropathy. The other is a case-control study of African American patients with nephropathy (cases) and their spouses (controls) unaffected by diabetes and nephropathy; offspring are genotyped when available to provide haplotype data. The specific goals of this program: * Delineate genomic regions associated with the development and progression of renal disease(s) * Evaluate whether there is a genetic link between diabetic nephropathy and diabetic retinopathy * Improve outcomes * Provide protection for people at risk and slow the progression of renal disease * Help establish a resource for genetic studies of kidney disease and diabetic complications by creating a repository of genetic samples and a database * Encourage studies of the genetics of progressive renal diseasegenetic susceptibility, genetic pathway, renal, kidney, outcome, gene, genetics, european-american, african-american, mexican-american, american-indian, linkage association study, admixture linkage disequilibrium, mapping by admixture linkage disequilibrium, serum creatinine, urinary protein excretion, plasma glucose level, blood pressure, blood lipid level, trait, linkage, adult human, male, female, clinicalSCR_001525( Family Investigation of Nephropathy of Diabetes , RRID:SCR_001525)NIDDK - National Institute of Diabetes and Digestive and Kidney Diseases NIDDKlisted by:, NIDDK Information Network, submitted by: NIDDK Information NetworkPMID:15642484Last checked downnlx_152825
American Society for ApheresisResource, portal, community building portal, data or information resourceAn organization of physicians, scientists, and allied health professionals whose mission is to advance apheresis medicine for patients, donors and practitioners through education, evidence-based practice, research and advocacy. ASFA represents a broad range of professionals involved in: donor apheresis, apheresis in transplantation & therapeutic apheresis.apheresis, donor, transplantation, therapeutic, clinical, bloodSCR_003967(American Society for Apheresis, RRID:SCR_003967)related to: Kidney Health InitiativeLast checked upnlx_158372
EORTC Clinical TrialsResource, catalog, data or information resource, clinical trial, databaseA database that contains information about EORTC (European Organisation for Research and Treatment of Cancer) clinical trials but also clinical trials from other organizations, in which EORTC has been/is participating. The protocol database may be browsed by EORTC Research Group, tumor site, treatment, or drug.clinical, protocolSCR_004011(EORTC Clinical Trials, RRID:SCR_004011)EORTC CancerLast checked upnlx_158511
Canadian Breast Cancer Foundation Tumor BankResource, biomaterial supply resource, biospecimen repository, tissue bank, service resource, storage service resource, data or information resource, material resource, material storage repositoryA tumor bank that provides a large collection of cancer specimens, from breast and other cancers, annotated with clinical information. The CBCF TB enables researchers to address unanswered questions concerning the prognosis and treatment of breast cancer and other cancers. The CBCF TB website is also directed to participants interested in donating tumor tissue or blood. Biological specimens such as blood, urine, bone marrow, and ascites (fluid that sometimes collects in the abdomen) contain genetic information, just as tumor tissue does. These samples can be used in studies that may help researchers see how people with certain genetic make-ups respond to certain treatments. It can also explain why different people have different health problems. CBCF TB, formerly ARTB, was created by a merger of components of two existing Tumor-banking initiatives, the CLS Repository in Calgary and the Tumor bank of the PolyomX Program in Edmonton.clinical information, clinicalSCR_004214(Canadian Breast Cancer Foundation Tumor Bank, RRID:SCR_004214)Canadian Breast Cancer Foundation Breast cancer, Tumor, CancerAlberta Cancer Foundation, Canadian Breast Cancer Foundationrelated to: Canadian Tumour Repository Network, listed by: One Mind Biospecimen Bank ListingLast checked upnlx_143637
North Texas Traumatic Brain Injury Model SystemResource, topical portal, portal, data or information resourceThe 16 affiliated Model System centers throughout the United States are responsible for gathering and submitting the core data set to the national database as well as conducting research studies on traumatic brain injury (TBI) both in collaboration with the other centers and within our own site. Through our research we hope to learn more about TBI and about the issues and concerns of people with TBI. Our goals are to improve the outcome and quality of life for people who have had brain injuries and for those who are caring for the person with a TBI. The North Texas Traumatic Brain Injury Model System (NT-TBIMS) pools the efforts and talents of individuals from the Departments of Neurosurgery, Neurology, Physical Medicine and Rehabilitation, Psychiatry (Neuropsychiatry), and Neuroradiology of the two leading medical institutions in the North Texas region. To be a patient involved in the research being conducted by the North Texas Traumatic Brain Injury Model System you must have suffered a TBI, be at least 16 years of age, have received initial treatment for the TBI at either Parkland Health and Hospital System or Baylor University Medical Center and then have received rehabilitative care at either Parkland, University Hospital Zale-Lipshy, or Baylor Institute for Rehabilitation. The patient must also be able to understand and sign an informed consent to participate or, if unable, have a family member or a legal guardian who understands the form sign the informed consent for the patient.brain injury, brain, injury, traumatic brain injury, clinical, researchSCR_005879(North Texas Traumatic Brain Injury Model System, RRID:SCR_005879)University of Texas Southwestern Medical Center; Texas; USA Traumatic Brain InjuryNational Institute on Disability and Rehabilitation ResearchLast checked upnlx_149440
BIOAIR - BIOmarkers in severe Chronic AIRway DiseaseResource, disease-related portal, topical portal, research forum portal, biomaterial supply resource, portal, material resource, data or information resourceTHIS RESOURCE IS NO LONGER IN SERVICE, documented August 23, 2016. Longitudinal Assessment of Clinical Course and BIOmarkers in severe Chronic AIRway Disease (BIOAIR) is a study within the European Network For Understanding Mechanisms Of Severe Asthma (ENFUMOSA). BIOAIR study involves studies of severe asthma. The 10% of all asthmatics who have the most difficult disease has a 5-year survival in level with severe cancer diseases, as well as account for half of the costs to society of asthma. Mechanisms for the development of severe asthma, however, is unknown. BIOAIR the project characterizes clinical Phenotype and biomarkers in a study involving 12 centers in nine European countries. In a longitudinal study comparing severe asthmatics with mild asthmatics and patients with COPD (Chronic obstructive pulmonary disease). Clinical data and medicine consumption are collected daily in over a year with the help of modern IT technology. Blood tests, urine samples, upphostningsprover and bronkialbiopsier are collected repeatedly and tested for a wide range of possible pathogenetic factors, including genotype.longitudinal, clinical, biomarker, chronic airway disease, phenotype, medication, clinical data, genotype, pathogen, lung diseaseSCR_006007(BIOAIR - BIOmarkers in severe Chronic AIRway Disease, RRID:SCR_006007)Karolisnka Biobank Asthma, Chronic obstructive pulmonary diseaselisted by: One Mind Biospecimen Bank ListingLast checked downnlx_151388
PatientCrossroadsResource, patient registry, topical portal, portal, people resource, data or information resourceA trusted third-party gatekeeper of patient data from participants in a rare disease ecosystem, collecting and managing the information in a scalable, cost-effective manner. Each patient registry provides critical disease knowledge which makes that disease easier to study, increasing the probability a treatment can be developed. PatientCrossroads takes a network approach to patient registry programs. Unlike companies that merely sell registry software, we offer a full range of administration, management, and genetic curation services. What does this consolidated, patient-centric approach to patient registries mean? * Patients can more easily find registries and provide their valuable data (including locations of blood and tissue samples as well as reports of diagnoses, disease symptoms, treatment usage, and lifestyle activities) * Patients can be confident in the privacy of their de-identified data and the knowledge that PatientCrossroads does not sell patient data * Researchers and pharmaceutical companies have a larger, more easily accessible pool of potential patients for research studies and clinical trials targeting specific rare diseases * Pharmaceutical companies can collect post-market surveillance data in a more scalable and cost-effective manner * Rare disease advocacy and research foundations can more easily organize their global patient populations for inclusion in trials and studiesdisease, treatment, clinical, patient, registry, drug discovery, clinical trial, research study, genetics, biorepositorySCR_006279(PatientCrossroads, RRID:SCR_006279)Rare diseaseLast checked downnlx_151889
CTE and Post-traumatic Neurodegeneration: Neuropathology and Ex Vivo ImagingResource, disease-related portal, topical portal, data or information resource, portal, research forum portalInitiative to assemble a multicenter team of expert neuroscientists to evaluate the late effects of Traumatic brain injury (TBI), including single and repetitive TBI of varying severity, and Chronic Traumatic Encephalopathy (CTE), using histological examination of postmortem bio specimens and neuroimaging tools as a foundation to develop in vivo diagnostics. As a first aim, this proposal will bring together a team of 5 accomplished neuropathologists in neurodegenerative disease to establish consensus criteria for the post-mortem diagnosis of CTE. This team will also define the stages of CTE pathology, the features that differentiate CTE from other neurodegenerations and the effects of substance abuse, and the characteristics of posttraumatic neurodegeneration after single TBI. As a second aim, this proposal will establish a national bio specimen and data bank for TBI (Understanding Neurological Injury and Traumatic Encephalopathy (UNITE) bio bank) by developing a nationwide brain donor registry and hotline to acquire high quality bio specimens and data. The UNITE bank will use strictly standardized protocols and a web-based interface to ensure that tissue and data are readily available to qualified investigators. Comprehensive retrospective clinical data including clinical symptoms, brain trauma and substance abuse history, and medical records (including common data elements) will be entered into a secure database. Behavioral/ mood dysfunction, cognitive changes, substance abuse and traumatic exposure will be correlated with quantitative assessment of the multifocal tauopathy, Ass deposition and axonal injury. As a third aim, neuroimaging signatures of the neuropathology will be determined in post-mortem tissue using high spatial resolution diffusion tensor imaging (DTI) and autoradiography using a highly selective PET ligand for tau. Quantitative assessment of axonal injury, tau, and Ass will be correlated with ex vivo DTI abnormalities and tau ligand autoradiography. Pilot neuroimaging studies of individuals at high risk for the development of CTE will also be conducted in the final 2 years of the proposal. This proposal will determine the clinical and neuroimaging correlates of CTE and posttraumatic neurodegeneration and create the groundwork for establishing their incidence and prevalence. This study will have a tremendous impact on public health of millions of Americans and greatly increase our understanding of the latent effects of brain trauma.brain bank, biospecimen repository, neuroimaging, brain, neuropathology, dti, pet, clinical, cognitive decline, dementia, axonal injury, aggregated protein, neurodegeneration, post-mortem, incidence, prevalence, risk factor, clinical course, treatment, diagnosis, biomarkerSCR_006543(CTE and Post-traumatic Neurodegeneration: Neuropathology and Ex Vivo Imaging, RRID:SCR_006543)Boston University School of Medicine; Massachusetts; USA Traumatic brain injury, Chronic traumatic encephalopathyLast checked upnlx_156786
International Database of Tetrahydrobiopterin DeficienciesResource, data or information resource, databaseTHIS RESOURCE IS NO LONGER IN SERVICE, documented on August 26, 2016. The BIODEF database have tabulated the most common clinical and laboratory data related to hyperphenylalaninaemia and tetrahydrobiopterin deficiencies. Additionally, there are data regarding treatment, outcome, and DNA analysis. Approximately 2% of newborns with hyperphenylalaninaemia are deficient in tetrahydrobiopterin. Selective screening must be performed in all instances where hyperphenylalaninaemia is detected by neonatal screening. In the last 20 years, 308 patients with tetrahydrobiopterin deficiencies have been recognized as a result of screening carried out, worldwide, in Departments of Paediatrics. Of these 308 patients, 181 suffered from 6-pyruvoyltetrahydropterin synthase deficiency, 92 from dihydropteridine reductase deficiency, 13 from pterin-4a-carbinolamine dehydratase deficiency, 12 from GTP cyclohydrolase I deficiency, and 10 are still unclassified. The BIODEF database have tabulated the most common clinical and laboratory data related to hyperphenylalaninaemia and tetrahydrobiopterin deficiencies. Additionally, there are data regarding treatment, outcome, and DNA analysis. Preliminary evaluation reveals that the degree of hyperphenylalaninaemia can vary from normal to 2500 mumol/L. Analyses of pterins in urine and measurement of dihydropteridine reductase activity from Guthrie cards are absolutely essential tests for accurate diagnosis. There is a regional (demographic) variation in the frequency of tetrahydrobiopterin deficiencies indicating the highest incidence in Saudi Arabia, probably a consequence of the high consanguinity rate.ethnic, frequency, 6-pyruvoyltetrahydropterin synthase deficiency, analysis, bh4, clinical, deficiency, demographic, diagnosis, dihydropteridine reductase deficiency, dna, gtp cyclohydrolase i deficiency, hyperphenylalaninaemia, measurement, neonatal, origin, outcome, pterin, pterin-4a-carbinolamine dehydratase deficiency, sex, tetrahydrobiopterin, treatment, urineSCR_008171(International Database of Tetrahydrobiopterin Deficiencies, RRID:SCR_008171)Last checked downnif-0000-21052
MagPro Magnetic StimulatorResource, material resource, resourceA complete line of non-invasive magnetic stimulation systems designed for clinical examinations and for research in the areas of neurophysiology, neurology, cognitive neuroscience, rehabilitation and psychiatry.experiment control, hardware, magnetic resonance, response monitoring, stimulus presentation, clinical, neurophysiology, neurology, cognitive neuroscience, rehabilitation, psychiatry, instrument, equipmentSCR_009601(MagPro Magnetic Stimulator, RRID:SCR_009601)listed by: NITRCLast checked upnlx_155803
Task Independent Fluctuations DiscussionResource, software resource, narrative resource, discussion, data or information resourceThe methodology and applications of task independent fluctuation measures including: connectivity maps of fMRI resting state scans, research using EEG/MEG/PET etc, methods to remove non-neural fluctuations, and applications to clinical, information resource, knowledge environment, model, magnetic resonance, other software resource, web environment, fmri, fmri resting state, eeg, meg, pet, non-neural fluctuation, clinicalSCR_009515(Task Independent Fluctuations Discussion, RRID:SCR_009515)listed by: NITRCLast checked upnlx_155677
Lumina LP- 400 Response SystemResource, material resource, resourceA reliable patient response system designed specifically for use in an fMRI. Lumina was developed to satisfy the requirements of both the clinical and research fields.experiment control, hardware, magnetic resonance, response monitoring, fmri, clinical, research, instrument, equipmentSCR_009596(Lumina LP- 400 Response System, RRID:SCR_009596)listed by: NITRCLast checked downnlx_155789
  1. RRID Portal Resources

    Welcome to the RRID Resources search. From here you can search through a compilation of resources used by RRID and see how data is organized within our community.

  2. Navigation

    You are currently on the Community Resources tab looking through categories and sources that RRID has compiled. You can navigate through those categories from here or change to a different tab to execute your search through. Each tab gives a different perspective on data.

  3. Logging in and Registering

    If you have an account on RRID then you can log in from here to get additional features in RRID such as Collections, Saved Searches, and managing Resources.

  4. Searching

    Here is the search term that is being executed, you can type in anything you want to search for. Some tips to help searching:

    1. Use quotes around phrases you want to match exactly
    2. You can manually AND and OR terms to change how we search between words
    3. You can add "-" to terms to make sure no results return with that term in them (ex. Cerebellum -CA1)
    4. You can add "+" to terms to require they be in the data
    5. Using autocomplete specifies which branch of our semantics you with to search and can help refine your search
  5. Collections

    If you are logged into RRID you can add data records to your collections to create custom spreadsheets across multiple sources of data.

  6. Facets

    Here are the facets that you can filter the data by.

  7. Further Questions

    If you have any further questions please check out our FAQs Page to ask questions and see our tutorials. Click this button to view this tutorial again.